Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 4:33 pm Sale |
2024-12-31 | 13G | TScan Therapeutics, Inc. TCRX |
K2 HealthVentures Equity Trust LLC | 3,602,700 6.900% |
-1,721,444 (-32.33%) |
Filing History |
| 2025-02-14 09:00 am Purchase |
2024-12-31 | 13G | TScan Therapeutics, Inc. TCRX |
Lynx1 Capital Management LP | 5,357,347 10.900% |
132,747 (+2.54%) |
Filing History |
| 2025-02-12 09:38 am Sale |
2024-12-31 | 13G | TScan Therapeutics, Inc. TCRX |
ADAGE CAPITAL PARTNERS GP LLC | 3,500,000 7.130% |
-400,000 (-10.26%) |
Filing History |
| 2024-11-14 4:40 pm Purchase |
2024-09-30 | 13G | TScan Therapeutics, Inc. TCRX |
BIOTECHNOLOGY VALUE FUND L P | 5,073,003 9.990% |
658,093 (+14.91%) |
Filing History |
| 2024-11-14 4:05 pm Purchase |
2024-09-30 | 13G | TScan Therapeutics, Inc. TCRX |
K2 HealthVentures Equity Trust LLC | 5,324,144 9.985% |
736,110 (+16.04%) |
Filing History |
| 2024-11-14 3:05 pm Sale |
2024-09-30 | 13G | TScan Therapeutics, Inc. TCRX |
Cormorant Asset Management LP | 0 0.000% |
-2,500,000 (Position Closed) |
Filing History |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | TScan Therapeutics, Inc. TCRX |
BLACKROCK INC BLK |
4,633,276 9.500% |
0 (Unchanged) |
Filing History |
| 2024-10-21 4:11 pm Purchase |
2024-09-30 | 13G | TScan Therapeutics, Inc. TCRX |
BLACKROCK INC BLK |
4,633,276 9.500% |
3,366,088 (+265.63%) |
Filing History |
| 2024-04-29 4:02 pm Purchase |
2024-04-19 | 13G | TScan Therapeutics, Inc. TCRX |
Cormorant Asset Management LP | 2,500,000 5.150% |
2,500,000 (New Position) |
Filing History |
| 2024-04-23 4:25 pm Purchase |
2024-04-19 | 13D | TScan Therapeutics, Inc. TCRX |
Baker Bros. Advisors LP | 2,828,938 6.100% |
35,000 (+1.25%) |
Filing History |
| 2024-02-14 4:45 pm Purchase |
2023-12-31 | 13G | TScan Therapeutics, Inc. TCRX |
K2 HealthVentures Equity Trust LLC | 4,588,034 9.985% |
2,488,225 (+118.50%) |
Filing History |
| 2024-02-09 4:08 pm Unchanged |
2023-12-31 | 13G | TScan Therapeutics, Inc. TCRX |
GV 2017, L.P. | 1,077,080 2.500% |
0 (Unchanged) |
Filing History |
| 2024-02-08 06:02 am Purchase |
2023-12-31 | 13G | TScan Therapeutics, Inc. TCRX |
Pitango HealthTech Fund I L.P. | 2,079,985 4.300% |
1,000,000 (+92.59%) |
Filing History |
| 2024-02-07 07:45 am Sale |
2023-12-31 | 13G | TScan Therapeutics, Inc. TCRX |
ADAGE CAPITAL PARTNERS GP LLC | 3,900,000 8.960% |
-100,000 (-2.50%) |
Filing History |
| 2023-06-12 4:30 pm Purchase |
2023-05-31 | 13G | TScan Therapeutics, Inc. TCRX |
ADAGE CAPITAL PARTNERS GP LLC | 4,000,000 9.350% |
4,000,000 (New Position) |
Filing History |
| 2023-06-08 1:25 pm Sale |
2023-05-31 | 13G | TScan Therapeutics, Inc. TCRX |
BLACKROCK INC BLK |
1,267,188 3.000% |
-246,758 (-16.30%) |
Filing History |
| 2023-06-05 4:45 pm Purchase |
2023-05-26 | 13G | TScan Therapeutics, Inc. TCRX |
BIOTECHNOLOGY VALUE FUND L P | 4,414,910 9.990% |
4,414,910 (New Position) |
Filing History |
| 2023-06-05 4:09 pm Purchase |
2023-05-26 | 13G | TScan Therapeutics, Inc. TCRX |
EcoR1 Capital LLC | 5,000,000 11.700% |
5,000,000 (New Position) |
Filing History |
| 2023-06-02 4:56 pm Purchase |
2023-05-31 | 13G | TScan Therapeutics, Inc. TCRX |
Lynx1 Capital Management LP | 5,224,600 12.200% |
5,224,600 (New Position) |
Filing History |
| 2023-06-02 4:06 pm Purchase |
2023-05-25 | 13D | TScan Therapeutics, Inc. TCRX |
Baker Bros. Advisors LP | 2,793,938 6.500% |
9,146 (+0.33%) |
Filing History |